Overview

Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Post marketing Surveillance to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) on health-related quality of life in COPD patients who stopped smoking during treatment and to obtain safety data regarding adverse events.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Tiotropium Bromide